These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9045296)

  • 21. Secondary myelodysplastic syndromes and acute leukemias.
    Zeidman A; Dayan DB; Mittelman M
    Haematologia (Budap); 1995; 27(1):23-8. PubMed ID: 12051292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
    Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
    Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biology and therapy of secondary leukaemias.
    Dann EJ; Rowe JM
    Best Pract Res Clin Haematol; 2001 Mar; 14(1):119-37. PubMed ID: 11355927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deregulation of homologous recombination DNA repair in alkylating agent-treated stem cell clones: a possible role in the aetiology of chemotherapy-induced leukaemia.
    Worrillow LJ; Allan JM
    Oncogene; 2006 Mar; 25(12):1709-20. PubMed ID: 16278672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma.
    Saso R; Kulkarni S; Mitchell P; Treleaven J; Swansbury GJ; Mehta J; Powles R; Ashley S; Kuan A; Powles T
    Br J Cancer; 2000 Jul; 83(1):91-4. PubMed ID: 10883674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
    Tebbi CK; London WB; Friedman D; Villaluna D; De Alarcon PA; Constine LS; Mendenhall NP; Sposto R; Chauvenet A; Schwartz CL
    J Clin Oncol; 2007 Feb; 25(5):493-500. PubMed ID: 17290056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia.
    Allan JM; Wild CP; Rollinson S; Willett EV; Moorman AV; Dovey GJ; Roddam PL; Roman E; Cartwright RA; Morgan GJ
    Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11592-7. PubMed ID: 11553769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benzene-induced acute myeloid leukemia: a clinician's perspective.
    Natelson EA
    Am J Hematol; 2007 Sep; 82(9):826-30. PubMed ID: 17506065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Etiology of acute myeloid leukemia in the elderly.
    Bowen DT
    Semin Hematol; 2006 Apr; 43(2):82-8. PubMed ID: 16616041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study.
    Behringer B; Pitako JA; Kunzmann R; Schmoor C; Behringer D; Mertelsmann R; Lübbert M
    Ann Hematol; 2003 Jul; 82(7):381-9. PubMed ID: 12756497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New agents for the treatment of acute myeloid leukemia.
    Tallman MS
    Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes.
    Ratain MJ; Rowley JD
    Ann Oncol; 1992 Feb; 3(2):107-11. PubMed ID: 1318741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapy-related acute myeloid leukemia: role of DNA repair].
    Guièze R; Ravinet A; Hermet E; Maliki Y; de Botton S; Bay JO
    Bull Cancer; 2011 Mar; 98(3):247-55. PubMed ID: 21427028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of DNA damage and repair upon the risk of treatment related leukemia.
    Guillem V; Tormo M
    Leuk Lymphoma; 2008 Feb; 49(2):204-17. PubMed ID: 18231906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapy related leukemias: susceptibility, prevention and treatment.
    Leone G; Voso MT; Sica S; Morosetti R; Pagano L
    Leuk Lymphoma; 2001 Apr; 41(3-4):255-76. PubMed ID: 11378539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Secondary acute myeloid leukemia following treatment with epipodophyllotoxins.
    Murphy SB
    J Clin Oncol; 1993 Feb; 11(2):199-201. PubMed ID: 8426194
    [No Abstract]   [Full Text] [Related]  

  • 38. A comparative analysis of alkylating agent and epipodophyllotoxin-related leukemias.
    Ellis M; Ravid M; Lishner M
    Leuk Lymphoma; 1993 Sep; 11(1-2):9-13. PubMed ID: 8220158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The epipodophyllotoxins: both sides of the coin.
    Rivera GK; Pui CH; Crist WM
    J Clin Oncol; 1993 Aug; 11(8):1624-5. PubMed ID: 8336199
    [No Abstract]   [Full Text] [Related]  

  • 40. [Second cancers associated with the cancer treatment and their possible control].
    Abe T; Nomura K
    Nihon Rinsho; 2003 Jun; 61(6):1045-51. PubMed ID: 12806958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.